0001544227-21-000007.txt : 20210209
0001544227-21-000007.hdr.sgml : 20210209
20210209163637
ACCESSION NUMBER: 0001544227-21-000007
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210201
FILED AS OF DATE: 20210209
DATE AS OF CHANGE: 20210209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Minai-Azary Jennifer Lynn
CENTRAL INDEX KEY: 0001844398
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35890
FILM NUMBER: 21607047
MAIL ADDRESS:
STREET 1: 110 MILLER AVENUE
STREET 2: SUITE 100
CITY: ANN ARBOR
STATE: MI
ZIP: 48104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Millendo Therapeutics, Inc.
CENTRAL INDEX KEY: 0001544227
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 451472564
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 110 MILLER AVENUE, SUITE 100
CITY: ANN ARBOR
STATE: MI
ZIP: 48104
BUSINESS PHONE: 734-845-9000
MAIL ADDRESS:
STREET 1: 110 MILLER AVENUE, SUITE 100
CITY: ANN ARBOR
STATE: MI
ZIP: 48104
FORMER COMPANY:
FORMER CONFORMED NAME: OvaScience, Inc.
DATE OF NAME CHANGE: 20120308
3
1
wf-form3_161290656696722.xml
FORM 3
X0206
3
2021-02-01
0
0001544227
Millendo Therapeutics, Inc.
MLND
0001844398
Minai-Azary Jennifer Lynn
C/O MILLENDO THERAPEUTICS, INC.
110 MILLER AVENUE, SUITE 100
ANN ARBOR
MI
48104
0
1
0
0
Chief Financial Officer
Stock Option (right to buy)
1.08
2023-08-21
Common Stock
2969.0
D
Stock Option (right to buy)
2.69
2024-05-27
Common Stock
989.0
D
Stock Option (right to buy)
4.44
2026-01-27
Common Stock
12382.0
D
Stock Option (right to buy)
8.47
2026-11-02
Common Stock
12840.0
D
Stock Option (right to buy)
16.4
2028-08-23
Common Stock
11160.0
D
Stock Option (right to buy)
10.48
2029-01-31
Common Stock
18000.0
D
Stock Option (right to buy)
11.59
2029-06-20
Common Stock
7000.0
D
Stock Option (right to buy)
7.94
2030-01-30
Common Stock
20000.0
D
Stock Option (right to buy)
2.0
2030-05-24
Common Stock
20000.0
D
Shares subject to this option are fully vested.
Twenty-five percent (25%) of the shares subject to this option vested on August 20, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Twenty-five percent (25%) of the shares subject to this option vested on January 31, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Twenty-five percent (25%) of the shares subject to this option vested on June 20, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Twenty-five percent (25%) of the shares subject to this option vested on January 31, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Fifty percent (50%) of the shares subject to this option vested on December 31, 2020, and one twelfth (1/12th) of the remaining shares subject to this option shall vest in equal monthly installments thereafter, subject to the Reporting Person continuing to provide service to the Issuer through each such date.
/s/ Jennifer L. Minai-Azary
2021-02-09